版本:
中国

BRIEF-Coherus Biosciences prevails in '135 IPR decision

May 16 Coherus Biosciences Inc:

* Coherus Biosciences prevails in '135 IPR decision

* Coherus Biosciences - patent trial, appeal board of U.S. Patent And Trademark Office ruled in favor of review of Abbvie's U.S. patent 8,889,135

* Coherus Biosciences-decision invalidates claims of patent that directed to method for treating rheumatoid arthritis by administering 40 MG of humira

* "Pleased that PTAB has decided to invalidate all claims of '135 patent" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐